American healthcare giant Johnson & Johnson (NYSE: JNJ) has undertaken an in-depth business review, publishing plans which include the launch of 20 new products by the end of the decade.
The company is working on new therapies in oncology, as well as for immune-mediated and neurological conditions, supporting growth of around 6% towards the end of the forecast period.
A newly-streamlined J&J, which like many big pharma firms has hived off its consumer health division, is looking ahead to replace lost revenues once blockbuster Stelara (ustekinumab) comes off patent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze